Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$17.90 USD

17.90
594,158

+0.93 (5.48%)

Updated Jun 4, 2024 11:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?

by Zacks Equity Research

Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.

Agenus (AGEN) Surges: Stock Moves 9.4% Higher

by Zacks Equity Research

Agenus (AGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal

by Zacks Equity Research

It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.

Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead

by Zacks Equity Research

Agenus (AGEN) enters into a collaboration agreement with Gilead to develop and commercialize up to five I-O therapies.

Why Is Agenus (AGEN) Up 11.6% Since Last Earnings Report?

by Zacks Equity Research

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agenus (AGEN) Q3 Loss Wider Than Expected, Pipeline in Focus

by Zacks Equity Research

Agenus (AGEN) reports a wider third-quarter loss. Revenues earned from collaborations exceeded expectations.

Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -16.00% and 18.98%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Agenus (AGEN) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Celyad (CYAD) Jumps: Stock Rises 6.8%

by Zacks Equity Research

Celyad (CYAD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

    Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 6.7%

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

      Agenus Receives Milestone Payment of $5 Million from Incyte

      by Zacks Equity Research

      Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.

        Implied Volatility Surging for Agenus (AGEN) Stock Options

        by Zacks Equity Research

        Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.

          Agenus (AGEN) Continue to Surge Higher?

          by Zacks Equity Research

          As of late, it has definitely been a great time to be an investor in Agenus Inc. (AGEN).

            Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper

            by Zacks Equity Research

            Zacks.com featured highlights include: Dollar Tree, Agenus, Huntsman, ArcelorMittal and International Paper

              Sanghamitra Saha headshot

              Step Beyond Bargain Hunting & Tap Rising P/E With 5 Stocks

              by Sanghamitra Saha

              Bet on these top-ranked stocks with rising P/E to realize outsized gains.

                Agenus (AGEN) Delivering Well on Its Pipeline Candidates

                by Zacks Equity Research

                We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.

                  Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

                  by Zacks Equity Research

                  Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

                    Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates

                    by Zacks Equity Research

                    Agenus (AGEN) delivered earnings and revenue surprises of 36.84% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                      Madhu Goel headshot

                      Agenus (AGEN) Reports Narrower than Expected Loss in Q2

                      by Madhu Goel

                      Agenus posts narrower than expected loss in the second quarter of 2018.

                        Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                        by Zacks Equity Research

                        In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.

                          Agenus (AGEN) Down 1.5% Since Earnings Report: Can It Rebound?

                          by Zacks Equity Research

                          Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Agenus' (AGEN) Q1 Loss Wider than Expected, Shares Down

                            by Zacks Equity Research

                            Agenus (AGEN) incurs wider-than-expected loss in Q1 and did not report any revenues during the quarter. The company expects to file six investigational new drugs in 2018.

                              Will Agenus (AGEN) Disappoint Investors This Earnings Season?

                              by Zacks Equity Research

                              Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.